Published in BMJ Clin Evid on March 20, 2015
NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med (2007) 3.99
Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med (1997) 2.98
A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol (2003) 2.00
Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res (2003) 1.90
The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol (1999) 1.73
Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol (2001) 1.68
An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol (1995) 1.61
The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res (2007) 1.48
Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol (1999) 1.48
The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol (1994) 1.45
Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol (2004) 1.42
Vitiligo puzzle: the pieces fall in place. Pigment Cell Res (2007) 1.39
Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol (2004) 1.39
Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39
Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol (2007) 1.34
Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol (1999) 1.25
Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology (1994) 1.22
Vitiligo. What is it? Is it important? JAMA (1978) 1.21
Autoantibodies in patients with vitiligo. Lancet (1969) 1.16
Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet (2004) 1.15
Squamous cell carcinoma in a patient with generalized vitiligo. J Am Acad Dermatol (2001) 1.14
New insights and new therapies in vitiligo. JAMA (2005) 1.09
PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol (1999) 1.02
A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet (2003) 0.99
Association of HLA-DR4 with vitiligo. J Am Acad Dermatol (1983) 0.97
Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study. Br J Dermatol (2012) 0.95
400 cases of vitiligo. A clinico-therapeutic analysis. Indian J Dermatol (1972) 0.94
Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry (1979) 0.93
Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. Int J Dermatol (1995) 0.91
Dendritic cell dynamics in progressive depigmentations. Distinctive cytokinetics of -dendritic cells revealed by electron microscopy. Arch Dermatol Forsch (1972) 0.88
Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol (2000) 0.88
Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol (2002) 0.87
Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J Am Acad Dermatol (2004) 0.86
Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol (1998) 0.85
Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol (1983) 0.85
Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol (1996) 0.85
Genetic nature of vitiligo. J Dermatol Sci (1992) 0.82
Surgical interventions for vitiligo: an evidence-based review. Br J Dermatol (2013) 0.80
Vitiligo. An overview of therapeutic approaches. Dermatol Clin (1993) 0.79
Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr (1984) 0.79
Guidelines for the treatment of vitiligo. Drugs (1992) 0.78
Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo. Dermatol Surg (2005) 0.78
The provocation of cutaneous disease; Köbner's isomorphic phenomenon. Arch Middx Hosp (1951) 0.78